Materials and methods related to microRNA-21, mismatch repair, and colorectal cancer
AssigneeThe Ohio State University
InventorsCarlo M. Croce, Nicola Valeri
Life of this patent
Estimating the term…
Abstract
The present invention discloses the discovery that miR-21 targets and down-regulates the core mismatch repair (MMR) recognition protein complex hMSH2 and hMSH6. Anti-sense miR-21 is therefore proven as therapeutic herein. Therefore, compositions, kits, therapies and other methods, including methods of treatment/amelioration of symptoms, are disclosed in the present invention.
Claims10
A method of modulating hMSH2 protein expression in tumor cells of a subject, wherein the subject has been diagnosed with colorectal cancer (CRC), the method comprising:
- administering a pharmaceutical composition of an effective amount of antisense miR-21;
- and
- increasing hMSH2 protein expression.
A method to treat a patient with colorectal cancer, comprising:
- identifying a patient with colorectal cancer having decreased hMSH2 expression;
- administering a pharmaceutical composition of an effective amount of antisense miR-21 to the patient having decreased hMSH2 expression, thereby increasing hMSH2 expression;
- and
- thereafter, administering a pyrimidine analog.
A method of reducing tumor volume in a subject, wherein the tumor comprises at least one tumor cell having decreased hMSH2 expression compared to a control, the method comprising:
- administering a pharmaceutical composition of an effective amount of antisense miR-21 to the subject, thereby increasing hMSH2 expression;
- and
- administering a pyrimidine analog to the subject.
Dependencies are inferred from the claim text.